Eli Lilly Gene Therapy Slashes Bad Cholesterol: Game Changer
Baca dalam 60 detik
- The therapy, a single intravenous dose, maintained LDL reductions exceeding 50% at 15 months in patients with heterozygous familial hypercholesterolemia.
- Data from 148 participants show a 58.
- 4% drop in LDL from baseline, outperforming existing PCSK9 inhibitors.
The therapy, a single intravenous dose, maintained LDL reductions exceeding 50% at 15 months in patients with heterozygous familial hypercholesterolemia. Data from 148 participants show a 58. 4% drop in LDL from baseline, outperforming existing PCSK9 inhibitors.
This gene therapy leverages lipid nanoparticle delivery to edit liver cells permanently, contrasting with Amgen’s Repatha and Novartis’s Leqvio that require repeated injections. If approved, it would become the first one-and-done treatment for high cholesterol, slashing healthcare costs and patient non-adherence. Analysts project peak sales exceeding $5 billion annually.
Eli Lilly’s move signals a strategic pivot to genetic medicines, following its $700 million acquisition of Prevail Therapeutics. The company now competes with Verve Therapeutics and CRISPR Therapeutics in the in-vivo gene editing space. Success would cement Lilly’s dominance in cardiometabolic diseases, complementing its obesity drug Zepbound.
Power Move: Eli Lilly’s gene therapy doesn’t just lower cholesterol—it rewrites the treatment paradigm. If approved, it will disrupt the $30 billion lipid market and force rivals to accelerate their gene-editing pipelines. The first-mover advantage here could define cardiovascular care for a generation.
This article was edited with AI assistance for readability. Read original here.
